about
Most efficient cocaine hydrolase designed by virtual screening of transition statesRecombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoningChronic neuropsychological sequelae of cholinesterase inhibitors in the absence of structural brain damage: two cases of acute poisoning.Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's diseaseKinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving groupCrystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesteraseButyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior(-)-Phenserine attenuates soman-induced neuropathologyFSH regulates acetycholine production by ovarian granulosa cellsSelective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentExcessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activityA mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein familySynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholAPOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study.A novel system for the efficient generation of antibodies following immunization of unique knockout mouse strainsDesign of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency.Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.Supporting precision medicine by data mining across multi-disciplines: an integrative approach for generating comprehensive linkages between single nucleotide variants (SNVs) and drug-binding sites.Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.Correlation of the dynamics of native human acetylcholinesterase and its inhibited huperzine A counterpart from sub-picoseconds to nanoseconds.Rate-determining step of butyrylcholinesterase-catalyzed hydrolysis of benzoylcholine and benzoylthiocholine. Volumetric study of wild-type and D70G mutant behavior.Pressure-induced molten globule state of human acetylcholinesterase: structural and dynamical changes monitored by neutron scattering.The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgeryPharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.Update on the pharmacological treatment of Alzheimer's diseaseDynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity.Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction.Rational design of an enzyme mutant for anti-cocaine therapeuticsComputational redesign of human butyrylcholinesterase for anticocaine medication.Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.The proline-rich tetramerization peptides in equine serum butyrylcholinesteraseMultipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybridsDesign, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine.Nongradient blue native gel analysis of serum proteins and in-gel detection of serum esterase activities.Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysisNaturally occurring variations in the human cholinesterase genes: heritability and association with cardiovascular and metabolic traits
P2860
Q24649976-3B96BA7C-2E2A-4286-8FE2-7F3F528D5E42Q24683895-0AE9BDFC-20F5-452F-9D5F-45481C5E962BQ24813278-65C7E8C4-FFA0-4DBC-ADB8-EFC5D5593D1EQ26999066-230079AB-C3F2-431A-9142-CD4879DA8A7EQ27677846-833F997D-DFD7-480B-8B0A-CC4BBBE2BC15Q27684632-766CFD92-4C84-45DB-B121-59C780B82004Q28393492-351AC217-EBE4-4705-9B7E-E6F4441ED10CQ28539914-26729A8F-62B0-41BD-BEB5-633A95760349Q28574522-6B016559-A93A-4999-9487-4AE5B0FC61B7Q28578059-86D159FB-BB17-426F-BE2F-400F971C759BQ28586552-0BC50D16-7BEE-443D-A229-9BAC8269EBF3Q28588470-EDF8462F-DA54-4C81-B017-F09AFC696B4DQ28818062-97411EF8-D679-4E7D-B7D5-40AB41714435Q29416986-DABDB923-6753-4B60-8F80-F5C5D1245652Q30394335-458469E0-5557-4E34-AAB0-2E9FF73AD8F0Q30394352-E4583454-3A69-4F09-AADC-775657963022Q30877329-9B805A52-8C9D-444E-B061-C8925D25F338Q31159438-D46FED4F-63F8-4954-9B4F-57167A59068AQ33335367-1CB9FE22-FCDD-432B-A855-FB4B409D2CFAQ33358518-6C5C238F-02C0-409B-A213-019AA6CDB2F4Q33431605-CDAC4DE4-0EC4-44C3-9305-5032066032EAQ33463711-9F7CD0FB-D5AE-4386-9FD4-914AE53774C2Q33630562-4B025214-CDA1-416B-AEE7-B8D0758C1A5AQ33708963-B379E4BB-F56A-433D-A1AB-82DCC92F3C4EQ33750604-798A1E73-B090-4F87-BB0C-B3796F732086Q33754836-EC90FB11-70CD-45F3-91CA-C78181B1869CQ33828536-675A0A78-2313-415B-A9E9-C4012999D440Q33836947-32534AE1-B41D-44C9-BEA9-C3E2558981A0Q33847761-43565944-E5B3-4FC9-A149-83BC38DD5408Q33860687-7F25919F-81D8-483E-8BC4-7E2456C27F13Q33873862-2EFD1759-705B-485B-943C-4241EA9BAEE6Q34133353-B0761069-00B1-4CE9-A9D9-A275BF5B3851Q34338594-93D9C665-DCC2-4847-9663-037199B5D0CDQ34378330-2BE50869-5508-4E92-91BD-3609D9A4D8AFQ34394212-6F2FC8BE-ADF8-4655-80C9-1DCB09B558DFQ34552012-2F189C8D-8B26-4DC0-8554-5D6DF5735065Q34556725-914F4B7C-F5CC-4560-BE32-0DAEC631413EQ34710672-FC8A15C0-633F-4785-9702-3570071659FFQ34743671-7EA4C038-F526-45C5-B50A-B2D237B44970Q35077944-96B9FA50-D3CE-4986-A2D7-B12AE8E31EF4
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neurobiology of butyrylcholinesterase.
@ast
Neurobiology of butyrylcholinesterase.
@en
type
label
Neurobiology of butyrylcholinesterase.
@ast
Neurobiology of butyrylcholinesterase.
@en
prefLabel
Neurobiology of butyrylcholinesterase.
@ast
Neurobiology of butyrylcholinesterase.
@en
P2860
P356
P1476
Neurobiology of butyrylcholinesterase
@en
P2093
Changiz Geula
David A Hopkins
P2860
P2888
P304
P356
10.1038/NRN1035
P407
P577
2003-02-01T00:00:00Z